Syon Capital’s iTeos Therapeutics ITOS Stock Holding History

Syon Capital’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-12,368	Closed	-$135K	–	494
2023 Q3	$135K	Buy	+12,368	New	+$158K	0.02%	356

Other funds holding ITOS

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Syon Capital's ITOS Position: Q4 2023 in Review

Syon Capital sold out of iTeos Therapeutics (ITOS) in Q4 2023, closing a stake of 12,368 shares — an estimated $135K sold.

Syon Capital first reported a position in ITOS in Q3 2023 and held it in 1 quarter. The position peaked at $135K in Q3 2023. 137 funds tracked by Wall St. Rank hold ITOS as of Q4 2023.

Syon Capital reported no remaining iTeos Therapeutics position as of Q4 2023 after selling out during the quarter.
Syon Capital sold 12,368 iTeos Therapeutics shares in Q4 2023, an estimated $135K.
Syon Capital first reported a position in iTeos Therapeutics in Q3 2023 and held it in 1 quarter.
Syon Capital's iTeos Therapeutics position peaked at $135K in Q3 2023.
137 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2023.

Based on Syon Capital's 13F filing for Q4 2023, filed 2 Feb 2024.